TL;DR
$5M products liability is the floor for most pharma and medical device sponsor MSAs; $10M appears for oncology, biologics, sterile injectable, and controlled-substance work. Going from $5M to $10M usually costs far less than double, because the added limit is normally an excess layer priced above the working primary. The $10M trigger is usually sponsor MSA wording, not statistical loss expectancy.
Products tower sizing
The products and completed operations tower is the single most important coverage line for most life-sciences operators. The sizing decision - typically between $5M and $10M, occasionally up to $25M or beyond - drives a meaningful share of total program premium and determines whether the operator is compliant with sponsor MSAs at the high end of the market.
This page covers the practical tradeoff: what each tower size satisfies, what it costs incrementally, and the breakpoints where stepping up from $5M to $10M moves from optional to mandatory.
Last updated 2026-10-16
Side-by-side
Frequently asked
Branded innovator sponsor MSAs, hospital purchase contracts at 503B scale, and most Class III medical-device GPO contracts typically require $10M products at minimum. Some innovator MSAs for biologics, oncology, or injectable products require $25M+. Generic-pharma sponsor MSAs typically accept $5M.
Usually far less than double. The added $5M is normally an excess layer sitting above the working primary, and excess limit is priced well below primary limit per million because fewer losses reach it. The delta grows with product class (sterile injectables and biologics cost more than oral solid dose), revenue, sponsor count and loss history. It is generally small next to the cost of losing a high-value engagement for non-compliance, and a coverage review prices it against your actual tower.
A products policy with $5M aggregate means total claims paid in one policy period are capped at $5M. A single $3M-$4M claim materially erodes the aggregate, leaving the operator under-insured for the remainder of the policy period. Operators serving multiple sponsors with shared aggregate face compounding exposure; per-project or per-location aggregate endorsements help.
Often yes - for two reasons. First, sponsor MSAs change at renewal; if a sponsor moves from $5M to $10M, the operator needs the tower ready. Second, aggregate exhaustion risk scales with sponsor count; multi-sponsor operators benefit from headroom even when no single MSA requires it.
Sometimes - specialty life-sciences markets writing monoline $10M occur. More commonly the tower is built in layers: $1M primary CGL/products + $4M umbrella + $5M excess from a second carrier. The layered structure is typically more economical than monoline at $10M.
How the number gets reached
Framing this as $5M versus $10M suggests a single policy gets larger. In practice almost nobody buys a $10M primary. They buy a modest primary and stack excess limit on top of it, and an insurance exhibit that asks for $10M is generally satisfied by a primary plus an excess layer that adds up to the demanded total. The exhibit cares about the combined number, not about how the tower was assembled.
That matters for cost, because the two structures do not price alike. Limit purchased above a working layer is materially cheaper per million than limit purchased at the bottom, where the losses actually attach. Moving from $5M to $10M is usually a far smaller budget change than the doubling implies, which is why the question is worth reopening when a contract asks for the higher figure.
The structural catch is that an excess layer only responds to what its schedule of underlying names. A tower assembled to hit a number, without confirming the layer follows form over products and completed operations, reaches the figure on the certificate and not necessarily on the claim. Where the contract language itself sets the target, sponsor MSAs and hospital contracts tend to state a combined limitrather than dictate the structure beneath it.
Free coverage review